Amicus Therapeutics filings document the former public company’s rare-disease biotechnology business, common stock registration, operating results, governance matters, shareholder voting disclosures, material agreements, risk factors, clinical or regulatory updates, and capital-structure information. The filing record includes Form 8-K reports for quarterly results, corporate updates, and material events tied to its business and securities.
Later filings document Amicus Therapeutics’ completed merger, its survival as a wholly owned subsidiary of BioMarin Pharmaceutical Inc., the removal of its common stock from Nasdaq listing through Form 25, and the termination or suspension of Exchange Act reporting obligations through Form 15. These documents record the company’s transition from a Nasdaq-listed issuer to a subsidiary within BioMarin.
Amicus Therapeutics director Lynn Dorsey Bleil reported disposing of her equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. In the transaction, she disposed of 113,941 shares of Common Stock at $14.50 per share and her holdings in this filing fell to zero.
The footnotes state that the disposition occurred upon consummation of the Merger and that each reported stock option was cancelled and converted into a cash payment based on $14.50 per share minus the applicable exercise price, multiplied by the number of option shares. The filing indicates that each option was fully vested or vested in full in connection with the Merger.
Amicus Therapeutics director Michael Aaron Kelly disposed of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical. He surrendered 72,468 shares of Common Stock at $14.50 per share, including 52,054 shares of Common Stock and 20,414 restricted stock units that vested at closing.
On the same date, several fully vested stock option grants covering 74,872, 42,467, 30,474, 45,423 and 36,111 shares of Common Stock were cancelled and converted into cash. For each option, the cash payment equaled the difference between the $14.50 merger price and the option’s exercise price, multiplied by the number of option shares. Following these transactions, the filing shows no remaining holdings from these awards.
AMICUS THERAPEUTICS director Michael Raab disposed of his equity in connection with the company’s acquisition by BioMarin Pharmaceutical. The filing shows 115,857 shares of Common Stock were cancelled at $14.50 per share, with the cash value paid as part of the merger consideration.
Footnotes state this amount included 95,443 Common shares and 20,414 restricted stock units that fully vested at closing. Multiple fully vested stock options were also cancelled and converted into cash based on the $14.50 per-share merger price minus each option’s exercise price. After these transactions, Raab reported zero remaining direct holdings or outstanding options.
Amicus Therapeutics Chief Accounting Officer Samantha Prout reported the cash-out of her equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical. She disposed of 125,951 shares of Common Stock at $14.50 per share, a figure that includes 47,394 shares of Common Stock and 78,557 restricted stock units that vested in full when the merger was consummated.
Several grants of fully vested stock options covering Amicus Common Stock were also cancelled at closing and converted into cash. For each option grant, she became entitled to a cash payment equal to the difference between the $14.50 merger price and the option’s exercise price, multiplied by the number of option shares. Following these transactions, the filing shows she no longer holds Amicus common shares or stock options.
AMICUS THERAPEUTICS, INC. Chief Development Officer Jeff Castelli reported disposing of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. In the transaction, he disposed of 427,089 shares of Common Stock at $14.50 per share, including 318,417 shares of Common Stock and 108,672 restricted stock units that vested in full at closing.
Several fully vested stock option awards were also cancelled and converted into the right to receive cash equal to $14.50 per share minus each option’s exercise price, multiplied by the option share count. Following these dispositions, the filing shows no remaining Common Stock or stock options held directly by Castelli.
Amicus Therapeutics’ Chief People Officer David Michael Clark disposed of his equity in connection with the company’s acquisition by BioMarin Pharmaceutical. The filing shows 221,811 shares of Common Stock were surrendered at $14.50 per share, including 130,942 shares and 90,869 restricted stock units that vested at closing.
Multiple fully vested stock option grants covering tens of thousands of shares each were cancelled and converted into cash. For each option, Clark became entitled to a cash payment equal to the excess of $14.50 over the option’s exercise price, multiplied by the shares subject to that option. Following these transactions, the Form 4 reports zero remaining direct holdings.
AMICUS THERAPEUTICS, INC. Chief Legal Officer Ellen Rosenberg reported disposing of her equity position in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. at $14.50 per share. The filing shows 463,898 directly held shares of common stock and related equity awards being cashed out as part of the merger terms.
An additional 15,000 shares of common stock held indirectly by her spouse were also disposed of at $14.50 per share. Several batches of stock options were cancelled and converted into cash based on the spread between the $14.50 merger price and their respective exercise prices, leaving no reported remaining options or common shares after the transaction.
Amicus Therapeutics Chief Financial Officer Simon N.R. Harford disposed of his equity in the company in connection with the consummation of its acquisition by BioMarin Pharmaceutical Inc.
The filing shows 143,595 shares of common stock were returned to the issuer at $14.50 per share, leaving Harford with zero directly held common shares. Footnotes explain that this disposition included 108,478 shares of common stock and 35,117 restricted stock units that vested in full when the merger closed.
Several stock option awards were also cancelled and converted into cash rights. Each option was exchanged for a cash payment equal to the difference between the $14.50 merger price and its exercise price, multiplied by the number of underlying shares. All reported options vested in full and, after these transactions, no stock options remain outstanding for Harford in this filing.
Amicus Therapeutics President and CEO Bradley L. Campbell reported the disposition of his equity interests in connection with the acquisition of Amicus by BioMarin Pharmaceutical. The filing shows 1,008,680 shares of Common Stock were disposed of, consisting of 689,467 shares and 319,213 restricted stock units that vested in full at closing of the merger.
The Form 4 also reports multiple stock option awards being disposed of to the issuer. Each option was cancelled at the merger closing and converted into a cash right equal to the excess of the $14.50 per share merger price over its exercise price, multiplied by the number of option shares. Following these transactions, the reported common shares and these options show zero remaining direct holdings.